Loading clinical trials...
Loading clinical trials...
Intratumoral Injection of SD-101, an Immunostimulatory CpG Oligonucleotide, in Combination With BMS- 986178, an OX40 Agonist Antibody, in Advanced Solid Malignancies [CA012-014]
Conditions
Interventions
Anti-OX40 Antibody BMS 986178
TLR9 Agonist SD-101
Locations
1
United States
Stanford Cancer Institute Palo Alto
Palo Alto, California, United States
Start Date
March 13, 2019
Primary Completion Date
October 4, 2021
Completion Date
October 4, 2021
Last Updated
November 22, 2023
NCT05372640
NCT04550494
NCT06311214
NCT05053971
NCT04704661
NCT05039801
Lead Sponsor
Ronald Levy
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions